Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
Elpida Therapeutics Mr Terry Pirovolakis Late Stage Preclinical Projects Pre-Clinical To Clinical Gene Therapy Development For CMT4J $3,930,964
AcuraStem Incorporated Mr. Samuel V. Alworth MS, MBA Late Stage Preclinical Projects Manufacturing of AS-202, an Antisense oligonucleotides for a Phase 1/2 Clinical Trial for Amyotrophic Lateral Sclerosis $0
Cedars-Sinai Medical Center Dr. Eugenio Cingolani Late Stage Preclinical Projects Extracellular Vesicles for Ventricular Tachycardia $1,050,000
City of Hope, Beckman Research Institute Prof. Karen S Aboody M.D. Late Stage Preclinical Projects Neural stem cell delivered CRAd-S-pk7 oncolytic viro-immunotherapy for ovarian cancer $5,314,547
Tr1X Inc. Maria Grazia Roncarolo Late Stage Preclinical Projects TRX103 for prevention of GvHD in patients receiving HLA mismatched related or unrelated allogeneic HSCT for the treatment of hematologic malignancies. $4,000,000
Mahzi Therapeutics Dr. Yael Weiss Late Stage Preclinical Projects Development of a Gene Therapy for the Treatment of WWOX related epileptic encephalopathy (WOREE) $4,000,000
University of California, Davis Mehrdad Abedi Late Stage Preclinical Projects Superior forward-oriented b-globin vector for treating Sickle Cell Disease $4,598,398
University of Southern California Mark Salman Humayun Late Stage Preclinical Projects IND-enabling program for PRPE-SF, the secretome from polarized stem cell-derived RPE cells, for the treatment of dry-age related macular degeneration $5,993,562
Stanford University Dr. Matthew H Porteus Late Stage Preclinical Projects Autologous Gene Corrected Sinus Basal Cells to Treat Serious Cystic Fibrosis Sinus Disease $6,000,000
University of California, Irvine Kyriacos A Athanasiou Late Stage Preclinical Projects Treatment of the TMJ disc complex $6,000,000
Aspera Biomedicines, Inc Catriona Jamieson Late Stage Preclinical Projects Cancer Stem Cell Interception with Rebecsinib: A First-in-Class ADAR1 Inhibitor $3,200,000
University of California, Los Angeles Dr. Jerome A. Zack Ph.D. Late Stage Preclinical Projects Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness $6,000,000
Kenai Therapeutics Howard J Federoff Late Stage Preclinical Projects Allogeneic iPSC derived Dopaminergic Drug Product for Parkinson’s disease $4,000,000
Rampart Bioscience Jeffrey Bartlett Late Stage Preclinical Projects Ex vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia $3,841,803
Nammi Therapeutics, Inc. Dr. David R Stover Late Stage Preclinical Projects IND-Enabling activities for the masked immunocytokine, QXL138AM $3,999,113
Calidi Biotherapeutics, Inc. 8587949607 Boris Minev Late Stage Preclinical Projects Allogeneic mesenchymal stem cells loaded with oncolytic virus for cancer treatment $3,111,467
Ossium Health, Inc. Dr. Brian Johnstone Late Stage Preclinical Projects Development of OSSM-007, cryopreserved interferon-gamma primed allogeneic MSCs, for treatment of steroid refractory acute graft versus host disease $3,457,858
University of California, Davis Dr. Joseph S Anderson Late Stage Preclinical Projects Hematopoetic stem cell gene therapy for the treatment of Tay-Sachs disease $3,998,253
Stanford University Natalia Gomez-Ospina Late Stage Preclinical Projects Genome Editing of Autologous Hematopoietic Stem Cells to Treat Severe Mucopolysaccharidosis type 1 (Hurler Syndrome) $4,900,977
University of California, San Francisco Dr. Karin Lindgren Gaensler Late Stage Preclinical Projects Development of TriLeukeVax, an Engineered Autologous Leukemia Vaccine for Stimulating Cytolytic Immune Responses to Residual Leukemic Stem Cells $6,000,000
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events $12,714,480
4D Molecular Therapeutics, Inc. Sara Collins Preclinical Stage Projects Gene Therapy for Alpha-1 Anti-Trypsin Deficiency $5,915,073
AcuraStem Incorporated Mr. Samuel V. Alworth MS, MBA Preclinical Stage Projects Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies $7,500,000
Cure Rare Disease Dr. Tahseen Mozaffar Preclinical Stage Projects Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 $7,292,297
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia $13,000,000
Savanna Biotherapeutics, Inc. Dr. Sunil Gandhi Ph.D Preclinical Stage Projects Microglia replacement therapy for CSF1R-related Leukoencephalopathy $12,993,456
Cedars-Sinai Medical Center Dr. David Joseph Lefer Preclinical Stage Projects TY1 and Semaglutide to Treat Cardiometabolic HFpEF $10,571,220
University of California, San Diego Dr. Stephanie Cherqui Preclinical Stage Projects CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia $7,423,504
Cedars-Sinai Medical Center Dr. Alessandra Ciullo Preclinical Stage Projects Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy $10,419,929
Navega Therapeutics Ana Maria Moreno Preclinical Stage Projects Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders $9,486,864
Scripps Health Dr. Darryl D. D’Lima Preclinical Stage Projects Stem Cell-Based Cartilage Tissue Regeneration $12,715,000
Stanford University Dr. Bertha Chen Preclinical Stage Projects Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence $7,275,596
Loma Linda University Hisham Abdel-Azim CCCE Grant Inland Empire and Desert Region CIRM Community Care Center of Excellence $9,000,000
Fresno Community Hospital and Medical Center Haifaa Abdulhaq CCCE Grant Establishing a CIRM Community Care Center of Excellence in the Central Valley $8,996,101
Lundquist Institute for Biomedical Innovation at Harbor – UCLA Medical Center Christina Wang CCCE Grant South Los Angeles Community Center of Excellence for Regenerative Medicine $9,000,000
Stanford University Dr. Michael P Snyder PhD ReMIND – Discovery Stage ReMIND Dissecting cell-specific genetic and molecular drivers of amyotrophic lateral sclerosis for therapeutic insights $12,999,837
Stanford University Sergiu P Pasca ReMIND – Discovery Stage ReMIND Transplantation of human forebrain assembloids as a platform for therapeutic screening in neurodevelopmental disorders $13,999,999
University of California, Los Angeles Daniel Geschwind ReMIND – Discovery Stage ReMIND Advancing Therapeutic Discovery Through Multimodal Analyses of Genetic and Cellular Mechanisms in Neuropsychiatric Disorders $13,957,175
University of California, San Diego Dr. Gene Wei-Ming Yeo ReMIND – Discovery Stage ReMIND Reversing age-dependent neurodegeneration by elimination of RNA pollution $13,000,000
Salk Institute for Biological Studies Christian Metallo ReMIND – Discovery Stage ReMIND Tracing the metabolic basis of neurological disorders $12,995,613
University of California, San Francisco Dr. Arnold Kriegstein ReMIND – Discovery Stage ReMIND Defining the Developmental Origins and Neuronal Regulation of Glioblastoma Stem Cells $13,578,858
University of California, San Diego Jonathan Sebat ReMIND – Discovery Stage ReMIND Modeling the genetic basis of psychopathology in schizophrenia and autism $12,703,708
University of California, San Francisco Mercedes Paredes ReMIND – Discovery Stage ReMIND Multi-gene modulation to rescue CNS-associated microdeletion syndromes $6,253,897
University of California, Los Angeles Aparna Bhaduri ReMIND – Discovery Stage ReMIND Defining Neurovascular Metabolism in Neurodevelopmental and Neuropsychiatric Disorders $10,330,000
University of California, San Francisco Tomasz Nowakowski ReMIND – Discovery Stage ReMIND CIRM Center for Neuropsychiatric Stem Cell Proteomics $13,781,522
Scripps Research Institute Xin Jin ReMIND – Discovery Stage ReMIND Translational epigenomics: dissecting cell type-specific function of neuropsychiatric risk genes in vivo $11,376,314
Scripps Research Institute Stuart A Lipton ReMIND – Discovery Stage ReMIND Multiomic Studies of Idiopathic Intellectual Disability and Autism Spectrum Disorder (ID/ASD) $17,365,387
University of California, San Francisco Alex Pollen ReMIND – Discovery Stage ReMIND Deep phenotyping of human brain organoid models of autism spectrum disorder to unravel disease heterogeneity and develop biomarkers and treatments $12,297,272
Coast to Coast Conferences & Events Calli France Conference – 2026 CIRM Trainee Network Conference CIRM Trainee Networking Conference 2026 $425,961
Coast to Coast Conferences & Events Calli France Conference – 2026 CIRM Trainee Network Conference 2025 CIRM Trainee Networking Conference $381,317
1 … 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

How to Apply

Learn More

Explore CIRM-Funded Clinical Trials

Learn More

Managing Your Grant

Learn More

See our Active Awards Portfolio

Learn More